Adding Imfinzi (durvalumab) to standard chemotherapy as the first-line treatment of adults with extensive-stage small cell lung cancer (SCLC) continues to show survival benefits sustained now for two years, updated findings from the CASPIAN trial show. The ongoing Phase 3 clinical trial (NCT03043872) supported Imfinzi’s recent approval by the U.S. Food and Drug Administration, after demonstrating that this combination reduced the risk of death by 27% compared to chemotherapy. CASPIAN recruited 805 SCLC patients, who were randomly assigned to…
You must be logged in to read/download the full post.
The post Imfinzi Plus Chemo Showing 2-year Survival Benefit in Advanced SCLC Study appeared first on BioNewsFeeds.